<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377559</url>
  </required_header>
  <id_info>
    <org_study_id>MYOTAX</org_study_id>
    <nct_id>NCT00377559</nct_id>
  </id_info>
  <brief_title>Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer</brief_title>
  <acronym>MYOTAX</acronym>
  <official_title>Phase II Multicentre Open Label Trial Evaluating the Efficacy and Safety of the Liposomal Doxorubicin (Myocet®) and Docetaxel (Taxotere®) Combination as First-line Treatment of Patients With Metastatic HER2/Neu Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open phase II multicentre study evaluating the efficacy and safety of the non
      pegylated liposomal doxorubicin (Myocet®) and docetaxel (Taxotere®) combination as first-line
      treatment of patients with metastatic HER2/neu negative breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II non comparative study, assessing the safety (primarily cardiac safety) and efficacy
      in patients with locally advanced or metastatic HER2/neu negative breast cancer not yet
      treated with chemotherapy for metastatic disease.

      Myocet and Taxotere will be given for a maximum of 6 cycles. Endpoints: cardiotoxicity (left
      ventricular ejection fraction decrease and/or symptoms of heart failure), serious other
      toxicity, disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiotoxicity (definite or probable cardiac death)</measure>
    <time_frame>treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Signs or symptoms of congestive heart failure (CHF), New York Heart Association (NYHA) class III-IV</measure>
    <time_frame>treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Decline in left ventricular ejection fraction (LVEF) of ≥ 5% to &lt; 50% with mild signs or symptoms of CHF (NYHA class &lt; III)</measure>
    <time_frame>treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Decline in LVEF of ≥ 10% to &lt; 50% without signs or symptoms of CHF</measure>
    <time_frame>treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of intercurrent events according to the National Cancer Institute - Common Terminology Criteria (NCI-CTC) classification</measure>
    <time_frame>treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to progression</measure>
    <time_frame>treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myocet+docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non pegylated liposomal doxorubicin and docetaxel</intervention_name>
    <description>max. 6 courses</description>
    <arm_group_label>1.</arm_group_label>
    <other_name>Myocet, Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histologically documented metastatic or locally advanced metastatic
             HER2/neu negative breast cancer.

          -  In the case of previous adjuvant or neoadjuvant chemotherapy with anthracyclines or
             taxanes, this must have been completed more than 12 months before inclusion.

          -  In the case of previous adjuvant or neoadjuvant chemotherapy, cumulative anthracycline
             dose ≤ 360 mg/m2 of doxorubicin or 600 mg/m2 of epirubicin or 75 mg/m2 of mitoxantrone
             on inclusion.

          -  Previous endocrine therapy is authorized (endocrine therapy other than goserelin must
             be stopped before starting treatment).

          -  Previous radiotherapy is authorized, if discontinued ≥ 4 weeks prior to inclusion in
             the study and if &lt; 10% of the bone marrow was within the irradiated area.

          -  Age ≥ 18 years.

          -  Performance status 0,1, or 2.

          -  Life expectancy ≥ 3 months.

          -  Evaluable disease.

          -  Normal LVEF (multigated acquisition [MUGA] scan or echocardiography).

          -  Normal haematological, hepatic and renal parameters: neutrophils ≥ 1.5 x 10^9/l;
             platelets ≥ 100 x 10^9/l; hemoglobin (Hb) ≥ 6 mmol/L; total bilirubin ≤ 1.5 times the
             upper limit of normal (ULN); transaminases ≤ 2.5 x ULN; alkaline phosphatase ≤ 2.5 x
             ULN; creatinine ≤ 1.5 x ULN.

          -  Dated and signed written informed consent.

        Exclusion Criteria:

          -  Previous chemotherapy for metastatic disease.

          -  History of other cancer, except for cervical carcinoma in situ treated by cone
             resection or basal cell or squamous cell skin cancer.

          -  History of congestive heart failure or myocardial infarction ≤ 1 year; cardiac
             function: NYHA ≥ 2 or LVEF &lt; 50%. Uncontrolled significant heart disease, such as
             unstable angina.

          -  Poorly controlled hypertension.

          -  Performance status 3, 4.

          -  Symptomatic or progressive brain metastases.

          -  Active infection or other serious underlying disease.

          -  Concomitant participation in other clinical trials.

          -  Pregnant women or nursing mothers; patients of childbearing potential without
             effective contraception.

          -  Absolute medical contraindication to the use of corticosteroid premedication.

          -  Allergy to polysorbate 80, doxorubicin, or egg lecithin.

          -  NCI-CTC grade &gt; 1 peripheral neuropathy.

          -  Patients not able to comply with regular medical follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence J. van Warmerdam, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina-Ziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <zip>9400 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina-Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5000 LC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mesos Medisch Centrum</name>
      <address>
        <city>Utrecht</city>
        <zip>3527 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <zip>5500 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri MC</name>
      <address>
        <city>Venlo</city>
        <zip>5900 BX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Walcheren</name>
      <address>
        <city>Vlissingen</city>
        <zip>4380 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Streekziekenhuis Koningin Beatrix</name>
      <address>
        <city>Winterswijk</city>
        <zip>7100 GG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2006</study_first_submitted>
  <study_first_submitted_qc>September 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <name_title>Raymond J.P. Schmidt, MD</name_title>
    <organization>Stichting (Foundation) BO3</organization>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>cardiotoxicity</keyword>
  <keyword>liposomal</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>docetaxel</keyword>
  <keyword>HER2/neu negative metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

